Evidence map›Paper›PMID 41382141›Full record

ArticleFluids and barriers of the CNS2025

A novel vector design targeting the blood-brain barrier with the brain-specific AAV-BR1 vector enables abluminal protein secretion from brain endothelial cells in vitro.

Bartosz Laczek, Maj Schneider Thomsen, Jakob Körbelin, Annette Burkhart, Torben Moos

Abstract read
In one paragraph

Article in Fluids and barriers of the CNS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bartosz LaczekNeurobiology Research and Drug Delivery, Department of Health Science and Technology, Aalborg University, Selma Lagerlöfs Vej 249, Room 11.02.012, Gistrup, DK-9260, Denmark.ORCID http://orcid.org/0000-0002-5209-9562
Maj Schneider ThomsenNeurobiology Research and Drug Delivery, Department of Health Science and Technology, Aalborg University, Selma Lagerlöfs Vej 249, Room 11.02.012, Gistrup, DK-9260, Denmark.ORCID http://orcid.org/0000-0002-8385-7039
Jakob KörbelinENDomics Lab, Department of Oncology, Hematology, and Bone Marrow Transplantation, University of Medical Center, Martinisstr. 52, 20246, Hamburg, Germany.ORCID http://orcid.org/0000-0002-5435-7182
Annette Burkhart *Neurobiology Research and Drug Delivery, Department of Health Science and Technology, Aalborg University, Selma Lagerlöfs Vej 249, Room 11.02.012, Gistrup, DK-9260, Denmark. abl@hst.aau.dk.ORCID http://orcid.org/0000-0003-2086-4693
Torben Moos *Neurobiology Research and Drug Delivery, Department of Health Science and Technology, Aalborg University, Selma Lagerlöfs Vej 249, Room 11.02.012, Gistrup, DK-9260, Denmark.ORCID http://orcid.org/0000-0001-9989-0207

Funding

Danmarks Frie Forskningsfond 1030-00474BLundbeck Foundation R155-2013-14113Scleroseforeningen R588-A40233
6 · The paper itself

Abstract

backgroundThe blood-brain barrier (BBB) formed by brain endothelial cells (BECs) limits the passage of biopharmaceuticals from the circulation to the brain parenchyma. Genetically modified BECs enable protein secretion to the brain and provide a novel strategy to obtain brain uptake of otherwise BBB-impermeable proteins. However, secretion from BECs may be bidirectional, thereby leading to off-target secretion into the blood. This study investigates a vector strategy using the brain-specific AAV-BR1 viral vector to achieve specific transduction of BECs and to subsequently direct the recombinant proteins towards an abluminal secretion pathway, thereby increasing the release of recombinant proteins into the brain.

methodsDifferent AAV-BR1 constructs, under the control of an endothelial-specific promoter (C-Ocln), were designed to include a fragment of the platelet-derived growth factor subunit B protein (PDGF-B) fused to the N-terminus of mCherry to promote abluminal secretion. Similar constructs using the more ubiquitous expressed CAG promoter were used for comparisons. The correct processing of the vector constructs was confirmed in vitro, including post-translational removal of the PDGF-B fragment by furin cleavage. AAV-BR1 vector constructs containing the C-Ocln promoter and the PDGF-B fragment were systemically administered in C57Bl/6J mice to evaluate abluminal secretion of mCherry to the brain parenchyma specifically by BECs. An in vitro BBB co-culture model based on primary mouse BECs and mixed glial cells was likewise used to evaluate if the PDGF-B fragment enhanced abluminal secretion of mCherry.

resultsThe C-Ocln promoter exhibited low specificity to BECs, off-target transduction of neurons, and low transduction efficiency, which complicated the in vivo quantification of mCherry secretion into the brain parenchyma. Modelling the BBB in vitro showed higher mCherry secretion across the abluminal membrane when the PDGF-B fragment was included in the vector construct, especially in combination with the CAG promoter.

conclusionInvestigating abluminal secretion of mCherry was complicated in vivo by high off-target transduction of neurons, despite using the endothelial-specific promoter (C-Ocln). In vitro results, however, suggest that incorporating a PDGF-B fragment into the vector design targets the recombinant protein for abluminal secretion by BECs and facilitates increased protein delivery to the brain.

Indexed as

Blood-Brain BarrierBrainEndothelial CellsGenetic VectorsAnimalsCells, CulturedDependovirusHumansMicePromoter Regions, GeneticAbluminal secretionBlood-brain barrierBrain gene therapyC-OclnEndothelial-specific promoterFurin cleavagePolarized secretionViral gene therapy

Identifiers

PMID41382141
PMCPMC12817821

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.